Readnour Robin Shane
SEC CIK 1914883 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | Dir | 624.8K | $2.71M | $428.4K | 11 | 2022-03-29 | 2026-09-09 |
Most active insiders at ANTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Readnour Robin Shane | Dir | — | $316.7K |
| 2 | Eizen Joshua M | See Remarks | — | $52.9K |
| 3 | FitzPatrick Margaret M | Dir | $11.6K | — |
| 4 | Chanda Sanjay | Chief Development Off | — | $9,311 |
| 5 | Day Lucy | CFO | — | $8,862 |
| 6 | Prior Stephen David | Chief Strategy Off | — | $7,363 |
| 7 | Williams Sarah Joanne | Principal Accounting Off | — | $3,025 |
| 8 | Trenor Cameron C. III | Chief Medical Off | — | — |
| 9 | Marks Gilbert Lynn | Dir | — | — |
| 10 | Martin Patricia A. | Dir | — | — |
Transactions 11
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MTI | 2026-09-11 19:45 | 2026-09-09 | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | S - Sale | $6.02 | -1,108 | 624.8K | -0.2% | -$6,675 |
| MTI | 2026-09-08 19:42 | 2026-09-03+ | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | S - Sale | $6.04 | -16.1K | 625.4K | -3% | -$97.3K |
| MTI | 2026-08-19 17:58 | 2026-08-17 | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | S - Sale | $6.01 | -35.4K | 633.9K | -5% | -$212.7K |
| 2024-12-23 | 2024-12-19 | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | A - Grant | $0.00 | +9,077 | 9,077 | New | $0 | |
| MI | 2024-12-10 | 2024-12-06+ | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | P - Purchase | $1.45 | +60.0K | 582.3K | +11% | +$86.8K |
| MI | 2024-11-27 | 2024-11-26+ | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | P - Purchase | $1.41 | +75.0K | 527.3K | +17% | +$105.8K |
| MI | 2024-11-21 | 2024-11-19+ | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | P - Purchase | $1.06 | +200.0K | 585.1K | +52% | +$213.0K |
| MI | 2024-01-17 | 2024-01-12 | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | S - Sale | $21.91 | -1,425 | 485.1K | -0.3% | -$31.2K |
| MI | 2024-01-12 | 2024-01-10 | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | S - Sale | $21.93 | -3,669 | 485.8K | -0.7% | -$80.4K |
| DMI | 2022-03-31 | 2022-03-29 | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | C - Cnv Deriv | — | +751.6K | 405.0K | New | — |
| DMI | 2022-03-31 | 2022-03-29 | ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Dir | P - Purchase | $15.00 | +153.3K | 487.6K | +46% | +$2.30M |
Purchase Sale Sale after option exercise All abbreviations